Niva Bupa shares slide 10% after block deal, wipes out recent gains

/2 min read

ADVERTISEMENT

Reports suggest that 13.2 crore shares are expected to be divested by True North-backed entity Fettle Tone and Niva Bupa Health Insurance MD and CEO, Krishnan Ramachandran.
Niva Bupa shares slide 10% after block deal, wipes out recent gains
Reports suggest that 13.2 crore shares are expected to be divested via the block deal. 

Shares of Niva Bupa Health Insurance slid nearly 10% over the past five days to ₹83, as of 2 pm on Monday, led by a sudden dip in the morning that wiped out the modest gains built through late May. Reports on a major stake sale by domestic private equity firm True North and Niva Bupa Health Insurance MD and CEO, Krishnan Ramachandran, likely triggered the share slump. 

Reports suggest that 13.2 crore shares are expected to be divested via the block deal.

True North-backed entity Fettle Tone and Ramachandran may offload up to 7.2% of the company’s equity through this transaction, news reports suggested.

The shares are being offered at ₹82 apiece, which is an 11% markdown from Friday’s closing price that was hovering around ₹93, valuing the deal at around ₹1,082 crore. Around 56.3 lakh shares reportedly exchanged hands in one of the block trades in the early trade activity.

Despite the recent volatility, the broader six-month trend for Niva Bupa remains positive. The stock has risen over 12% since the beginning of the year, climbing from around ₹74 to over ₹83. It gained momentum in April and May, driven by improving investor sentiment and steady operational performance. However, the June correction may reflect profit-booking or reactions to company-specific developments or regulatory cues.

fortune magazine cover
Fortune India Latest Edition is Out Now!
Netflix’s India Decade

January 2026

Netflix, which has been in India for a decade, has successfully struck a balance between high-class premium content and pricing that attracts a range of customers. Find out how the U.S. streaming giant evolved in India, plus an exclusive interview with CEO Ted Sarandos. Also read about the Best Investments for 2026, and how rising growth and easing inflation will come in handy for finance minister Nirmala Sitharaman as she prepares Budget 2026.

Read Now

Looking ahead, the company’s valuation remains relatively high with a P/E ratio of 69.46 and a market cap of ₹15,240 crore. The share is still trading well above its 52-week low of ₹68.54, but also far from its 52-week high of ₹109.34. For long-term investors, the recent dip may present a buying opportunity, but sustained performance will depend on the company’s ability to maintain profitability and navigate sectoral challenges in the health insurance space.

Explore the world of business like never before with the Fortune India app. From breaking news to in-depth features, experience it all in one place. Download Now